Cargando…

Central versus Peripheral CTEPH—Clinical and Hemodynamic Specifications

Background and Objectives: Chronic thromboembolic pulmonary hypertension (CTEPH) is a chronic progressive disease, resulting from persistent arterial obstruction combined with small-vessel remodeling. Central and peripheral CTEPH are distinguished, according to the dominant lesion’s location. This i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaldararova, Monika, Simkova, Iveta, Bohacekova, Marcela, Reptova, Adriana, Hlavata, Tereza, Pacak, Jozef, Lindner, Jaroslav, Jansa, Pavel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696046/ https://www.ncbi.nlm.nih.gov/pubmed/36363494 http://dx.doi.org/10.3390/medicina58111538

Ejemplares similares

Congenital Absence of the Portal Vein as a Rare Cause of Portopulmonary Hypertension—A Case Study Series
por: Hlavata, Tereza, et al.
Publicado: (2022)

Epidemiology of chronic thromboembolic pulmonary hypertension (CTEPH) in the Czech Republic
por: Jansa, Pavel, et al.
Publicado: (2022)

Riociguat in Patients with CTEPH and Advanced Age and/or Comorbidities
por: Barnikel, Michaela, et al.
Publicado: (2022)

NOVEL CTEPH MIMICKERS IN THE COVID-19 ERA
por: Pietrowicz, Rylie, et al.
Publicado: (2022)

The risk profile change in patients with severe chronic thromboembolic pulmonary hypertension treated with subcutaneous treprostinil
por: Jansa, Pavel, et al.
Publicado: (2023)

Beneficial effects of riociguat on hemodynamic responses to exercise in CTEPH patients after balloon pulmonary angioplasty – A randomized controlled study
por: Aoki, Tatsuo, et al.
Publicado: (2020)

Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
por: Escribano-Subias, Pilar, et al.
Publicado: (2019)

Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH
por: Gall, Henning, et al.
Publicado: (2018)

Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH
por: Benza, Raymond L., et al.
Publicado: (2020)

Cardiopulmonary exercise testing and pulmonary function testing for predicting the severity of CTEPH
por: Zhu, Hanqing, et al.
Publicado: (2021)

Pulmonary artery sarcoma presenting as chronic thromboembolic pulmonary hypertension (CTEPH)
por: Ampatzidou, Fotini, et al.
Publicado: (2023)

Local and Systemic RAGE Axis Changes in Pulmonary Hypertension: CTEPH and iPAH
por: Moser, Bernhard, et al.
Publicado: (2014)

Quality of initial anticoagulant treatment and risk of CTEPH after acute pulmonary embolism
por: Boon, Gudula J. A. M., et al.
Publicado: (2020)

Haemodynamic effects of riociguat in CTEPH and PAH: a 10-year observational study
por: Yang, Suqiao, et al.
Publicado: (2021)

Variation of PetCO(2) during incremental exercise and severity of IPAH and CTEPH
por: Sun, Xingxing, et al.
Publicado: (2022)

Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension: Impact on Clinical and Hemodynamic Parameters, Quality of Life and Risk Profile
por: Jansa, Pavel, et al.
Publicado: (2020)

Dual-energy Computed Tomography Delayed Myocardial Enhancement in the Diagnostic Dilemma of True versus False Left Ventricular Aneurysm – A Case Report
por: Berecova, Zuzana, et al.
Publicado: (2021)

Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension
por: Skoro-Sajer, Nika, et al.
Publicado: (2018)

Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences
por: Andersen, Asger, et al.
Publicado: (2017)

Correction: Quality of initial anticoagulant treatment and risk of CTEPH after acute pulmonary embolism
por: Boon, Gudula J. A. M., et al.
Publicado: (2020)

The Inflammatory Profile of CTEPH-Derived Endothelial Cells Is a Possible Driver of Disease Progression
por: Smolders, Valérie F. E. D., et al.
Publicado: (2021)

Elevated lipoprotein A in acute on chronic CTEPH with cardiogenic shock: a case report
por: Kyaw, Kyaw, et al.
Publicado: (2021)

Inherited Thrombophilia in Chinese CTEPH Patients: A Rather Common Finding in an Uncommon Condition
por: Kearney, Katherine, et al.
Publicado: (2022)

ANA Negative Systemic Lupus Erythematosus Leading to CTEPH, TTP-Like Thrombocytopenia, and Skin Ulcers
por: Changal, Khalid Hamid, et al.
Publicado: (2016)

Reply to comments and questions of Dr. Correale et al. about our review concerning CTEPH
por: Schölzel, Bastiaan E., et al.
Publicado: (2015)

Revisiting a Distinct Entity in Pulmonary Vascular Disease: Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
por: Sharma, Munish, et al.
Publicado: (2021)

Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH Registry
por: Guth, Stefan, et al.
Publicado: (2021)

Balloon pulmonary angioplasty in the current era of CTEPH treatment: How did we get here?
por: Yang, Jenny Z., et al.
Publicado: (2023)

Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)
por: Ghofrani, Hossein A, et al.
Publicado: (2009)

Mid-regional pro-atrial natriuretic peptide and copeptin as indicators of disease severity and therapy response in CTEPH
por: Kriechbaum, Steffen D., et al.
Publicado: (2020)

Lung Ventilation/Perfusion Scintigraphy for the Screening of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Which Criteria to Use?
por: Le Pennec, Romain, et al.
Publicado: (2022)

Radiological differences between chronic thromboembolic pulmonary disease (CTEPD) and chronic thromboembolic pulmonary hypertension (CTEPH)
por: Capone, Carmine, et al.
Publicado: (2021)

An unusual case of CTEPH treated by BPA in a patient with a single lung after cancer surgery
por: Darocha, Szymon, et al.
Publicado: (2022)

Regression of Tricuspid Regurgitation after Pulmonary Endarterectomy
por: Lindner, Jaroslav, et al.
Publicado: (2015)

Computed tomography angiographic parameters of pulmonary artery as prognostic factors of residual pulmonary hypertension after pulmonary endarterectomy
por: Niznansky, Matus, et al.
Publicado: (2021)

Chronic Thromboembolic Pulmonary Hypertension (CTEPH): A Review of Another Sequel of Severe Post-Covid-19 Pneumonia
por: Cueto-Robledo, Guillermo, et al.
Publicado: (2023)

SARS-COV-2 INFECTION AFTER CTEPH DIAGNOSIS ASSOCIATED WITH VASCULAR TISSUE FRIABILITY DURING PULMONARY THROMBOENDARTERECTOMY
por: Jonnalagadda, Anil Kumar, et al.
Publicado: (2022)

Hemodynamic Differences Between Central ECMO and Peripheral ECMO: A Primary CFD Study
por: Gu, Kaiyun, et al.
Publicado: (2016)

Endovascular Revascularization Improves the Central Hemodynamics and Augmentation Index in Patients with Peripheral Artery Disease
por: Watanabe, Ken, et al.
Publicado: (2019)

Fabry Disease in Slovakia: How the Situation Has Changed over 20 Years of Treatment
por: Jurickova, Katarina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q4iaerl5ts3jgk59jsu297n2u6